Summit Therapeutics (SMMT) Sinks After FDA Rejects Lung Cancer Drug Ivonescimab
Nov 16, 2026 · Trading Tips
The FDA said no on Sunday to one of biotech's most closely watched cancer drugs, and Summit Therapeutics (SMMT) is taking the hit Monday. The agency declined to approve ivonescimab, the PD-1/VEGF antibody Summit licensed from China's Akeso, for previously treated EGFR-mutated non-small-cell lung cancer.
Premarket moves ranged from roughly 14% to nearly 20% depending on the print, with Reuters putting the drop close to the high end. Akeso's Hong Kong shares fell as much as 32%.
The reason is narrow and specific. As MarketWatch reported, the agency wants a statistically significant improvement in overall survival. A "positive trend" or a post-hoc analysis won't do it.
The Phase 3 HARMONi trial did show a benefit on progression. Patients on ivonescimab plus chemotherapy had a 48% lower risk of cancer progression or death than those on chemo alone, according to a Seoul Economic Daily summary of New York Times and Reuters coverage.
But overall survival, the measure of how long patients actually live, missed statistical significance at the prespecified final analysis.
Summit points to later follow-up data showing a consistent survival benefit in both Asian and Western patients. Those analyses came after the original plan, and they didn't change the FDA's call.
That gap is the whole story. Progression data says the cancer stayed in check longer. Survival data says patients lived longer. The FDA wants the second one, and the trial didn't deliver it on the planned analysis.
The stakes go beyond one stock. Summit paid up to $5 billion in 2022 for U.S., Canadian, European and Japanese rights, and the drug has been on sale in China since 2024.
A China-run trial also reported it beating Merck's Keytruda on tumor progression, which is why so many people were watching. For Chinese biotech, it was supposed to be proof of concept for global drugs.
"The HARMONi filing was always at risk: the study did not demonstrate a statistically significant overall survival benefit at its prespecified final analysis…" — Daina Graybosch, Analyst, Leerink Partners
Here's the stock-specific read. Summit was already down 19.2% this year heading into the news, while the SPDR S&P Biotech ETF (XBI) had gained 23.9%. The market was hedging this outcome before the letter arrived.
Graybosch herself told investors to expect only a "modestly negative reaction" in the stock. That's a notable framing: the miss was seen as a known risk, not a shock.
The bull case hasn't vanished. The FDA's decision covers this one application for one group of lung cancer patients. Summit is testing ivonescimab in colorectal cancer and renal cell carcinoma, plus combination studies with other drugmakers.
AstraZeneca recently put $2 billion of equity into the company, which is a vote of confidence from a very large partner.
The risk is that the FDA has now written down exactly what it wants. Any resubmission or future filing will be judged on overall survival, and the company can't talk its way around that.
Biotech names built around one lead asset carry this kind of binary exposure. Monday is what it looks like when the binary goes the wrong way.
What to watch next: how Summit describes its path forward with the FDA, and whether it can generate the survival data the agency asked for.
Also watch what the other trials show on overall survival, and AstraZeneca's tone. Its commitment is the best signal of how big players view the pipeline after this setback.
If you own SMMT, ask which thesis you bought. A near-term U.S. lung cancer launch just got pushed out. A multi-indication pipeline bet is still intact, but it now rests on survival numbers that haven't arrived yet.
Bottom line: the FDA didn't close the door on ivonescimab, but it told Summit exactly what it will take to walk through it.